Spotlight on Silo Pharma Inc. (SILO): Ketamine


Ketamine shows promise in treating Alzheimer’s disease, Parkinson’s disease as well as depression, suicidal ideation and more

In 2021, Silo Pharma (OTCQB: SILO) entered a joint venture with Zylö Therapeutics to “explore the clinical development of ketamine using ZTI’s Z-pod (transdermal) technology”. This innovative technology allows Silo, an early-stage biopharmaceutical company, to develop a ketamine delivery system for people with dysphagia, difficulty or complete inability to swallow.(1) Silo Pharma is exploring the efficacy of ketamine in the treatment of patients suffering from both Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). More than 80% of Parkinsonian patients(2) and 75% of AD patients(3) suffer from dysphagia.

According to Dr. Jay Blankenship, Vice President of Business Development at Zylö Therapeutics, “Ketamine is an incredibly versatile drug that continues to show promise with new therapeutic indications.” Eric Weisblum, CEO of Silo Pharma, believes that “the ability to deliver ketamine (through the skin) over a prolonged period will allow us to explore both the safety and efficacy of our therapeutics…We believe that Zylo’s patented technology will allow us to reach potential patients who suffer from dysphagia.Currently, ketamine is administered intravenously, through the bone tissue (intraosseous), intramuscularly, orally or intranasally (through the nose), impractical, painful, and sometimes nausea-prone methods.(4)

Ketamine has been available for over “half a century…first synthesized in 1962 by Calvin Stevens at Parke-Davis Co (now Pfizer) as an alternative anesthetic for phencyclidine.” Ketamine facilitates “hypnotic (sleep-producing), analgesic (pain relief), and amnesic (short-term memory loss) effects; no other drug used in clinical practice produces these three important effects at the same time. Ketamine is a standard in operating rooms. Due to its “bronchial dilator profile”, ketamine is the safest choice for patients with “asthma and acute life-threatening bronchial constriction” and is “preferred in patients with unstable hemodynamics (blood flow ). Ketamine is also one of the few drugs approved for induction of anesthesia in caesarean sections. It is considered the agent of choice in children and severe burns. »(5)

New uses for ketamine show promise in treatment PD-related depression as well as dyskinesias, resulting from the side effects of levodopa treatments. Dyskinesia includes involuntary, erratic and writhing movements of the face, arms, legs and/or trunk.

“Recent clinical findings suggest that ketamine may provide neuroprotection and reduce neuropsychiatric symptoms associated with AD.”(6) Neuropsychiatric symptoms include agitation, depression, apathy, delusions, hallucinations and sleep disturbances. Ketamine has also been studied to help with suicidal ideation, as well as “eating disorders, problematic substance use, post-traumatic stress, and anxiety…”(7)

In October 2021, Silo entered into a subsidized research agreement with Columbia University incorporating the work of Dr. Christine Ann Denny. According to a Silo Pharma press release, “Dr. Denny’s pioneering research into whether ketamine…can improve memory retrieval, halt or even reverse the process of Alzheimer’s disease linked to memory loss or cognitive aging, could have life-changing implications for people suffering from everything from Alzheimer’s disease to post-traumatic stress disorder (“PTSD”).

Weisblum said, “Being able to bring hope and eventual therapy to patients suffering from Alzheimer’s disease (and potentially other conditions) is an exciting proposition for Silo Pharma. The unique compounds being developed at Columbia have shown great promise, and we look forward to continuing to explore and develop these therapies. »

Illustration reproduced with the kind permission of Therapeutic Zylö.

For the latest news from Silo Pharma, Click here.

Pharmaceutical Silo
560 Sylvain Avenue, suite 3160
Englewood Cliffs, NJ 07632

(2) Suttrup, I., Warnecke, T. Dysphagia in Parkinson’s disease. Dysphagia 31, 24–32 (2016).
(3) Yaprak Seçil, Şehnaz Arıcı, Tülay Kurt İncesu, Nevin Gürgör, Yeşim Beckmann, CumhurErtekin, 2016, Neurophysiologie Clinique/Clinical Neurophysiology
(4) Use of Ketamine in Current Clinical Practice
Mei Gao, Damoon Rejaei, Hong Liu
Acta Pharmacol Sin. Jul 2016; 37(7): 865–872. Published online March 28, 2016. doi: 10.1038/aps.2016.5
(5) Same
(6) Mohammad Shehata I, Masood W, Nemr N, Anderson A, Bhusal K, Edinoff AN, Cornett EM, Kaye AM, Kaye AD. The possible application of ketamine in the treatment of depression in Alzheimer’s disease. International Neurology. 2022; 14(2):310-321.
(7) University of British Columbia Okanagan Campus. “Exploring Therapeutic Uses of Ketamine: The Drug Could Be a Game-Changer in the Treatment of Mental Illness.” ScienceDaily. ScienceDaily, March 18, 2022. .

For more information, visit the company’s website at

NOTICE TO INVESTORS: The latest SILO news and updates are available from the company’s newsroom at

About InvestorWire

InvestorWire is the transfer service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wired broadcast products you’ll need to ensure your next press release grabs your target audience’s attention and stays with you. While our competitors come at you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all national versions. While other delivery services can provide a basic review of your release, InvestorWire helps you put your best foot forward with Improved press release.

With our competitors, the job is done the second your version crosses the line. Not with InvestorWire. We include follow-up coverage of each release taking advantage of the ever-growing audiences of the 50+ brands who make up the InvestorBrandNetwork.

Get the most out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit

Please review the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever posted or republished:

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, California 90046
310.299.1717 Office
[email protected]

InvestorWire is part of the InvestorBrandNetwork.


Comments are closed.